文献速递神经肿瘤

建立快速患者来源异种移植模型以预测恶性胶质瘤化疗药物敏感性/耐药性

The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.
PubMed 文献 · Neuro Oncol · 2023-01-01

研究采用鸡胚绒毛尿囊膜(CAM)培养体系建立快速患者来源异种移植模型,60例高级别胶质瘤患者中59例新鲜组织碎片在7天内成功植入,成瘤率98.3%,模型再现原发肿瘤组织学与分子特征;在14例患者的概念验证研究中,CAM异种移植对替莫唑胺或卡铂的反应与患者临床反应相关性为100%。

要点

  • 60例高级别胶质瘤患者中59例新鲜肿瘤组织碎片在7天内成功建立CAM异种移植,成瘤率98.3%。
  • CAM异种移植再现原发肿瘤的组织学与分子特征,单个碎片成瘤能力可预测患者预后不良。
  • 14例患者概念验证研究中,CAM异种移植对替莫唑胺或卡铂的反应与患者临床反应相关性为100%。

核心结论

  • CAM-胶质瘤模型是一种快速可靠的检测方法,有潜力作为药物发现的补充模型和实时Avatar平台,预测高级别胶质瘤患者的最佳治疗。

研究设计与样本

  • 采用快速高效的鸡胚绒毛尿囊膜(CAM)离体培养体系,评估高级别胶质瘤(HGG)患者的肿瘤药物敏感性。

主要发现

  • 60例患者中59例新鲜胶质瘤组织碎片在7天内成功建立CAM肿瘤异种移植,成瘤率98.3%,包括难以生长的IDH突变样本。
  • CAM异种移植忠实再现原发肿瘤的组织学与分子特征,单个碎片成瘤能力可预测患者预后不良。
  • 药物敏感或耐药异种移植的治疗表明,CAM-胶质瘤检测可在与患者给药剂量一致的条件下测试肿瘤对替莫唑胺和卡铂的敏感性。
  • 在涉及14例HGG患者的概念验证研究中,CAM异种移植对替莫唑胺或卡铂的反应与患者临床反应相关性为100%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-grade gliomas (HGG) are aggressive brain tumors associated with short median patient survival and limited response to therapies, driving the need to develop tools to improve patient outcomes. Patient-derived xenograft (PDX) models, such as mouse PDX, have emerged as potential Avatar platforms for personalized oncology approaches, but the difficulty for some human grafts to grow successfully and the long time required for mice to develop tumors preclude their use for HGG. METHODS: We used a rapid and efficient ex-ovo chicken embryo chorioallantoic membrane (CAM) culture system to evaluate the efficacy of oncologic drug options for HGG patients. RESULTS: Implantation of fresh glioma tissue fragments from 59 of 60 patients, that include difficult-to-grow IDH-mutated samples, successfully established CAM tumor xenografts within 7 days, with a tumor take rate of 98.3%. These xenografts faithfully recapitulate the histological and molecular characteristics of the primary tumor, and the ability of individual fragments to form tumors was predictive of poor patient prognosis. Treatment of drug-sensitive or drug-resistant xenografts indicates that the CAM-glioma assay enables testing tumor sensitivity to temozolomide and carboplatin at doses consistent with those administered to patients. In a proof-of-concept study involving 14 HGG patients, we observed a correlation of 100% between the CAM xenograft response to temozolomide or carboplatin and the clinical response of patients. CONCLUSION: The CAM-glioma model is a fast and reliable assay that has the potential to serve as a complementary model to drug discovery and a real-time Avatar platform to predict the best treatment for HGG patients.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Charbonneau M, Harper K, Brochu-Gaudreau K, et al. The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors. Neuro Oncol. 2023. PMID: 36821432. doi:10.1093/neuonc/noad047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。